热门关键字:经济学家    部委学者

微信咨询

微信咨询

手机网站二维码

手机网站

热门

智库专家

专家动态

当前位置:网站首页 >> 智库专家 >> 查看详情
Gavin Painter

Gavin Painter

GavinPainter,ProfessorofVictoriaUniversityofWellington,LowerHutt,NewZealand.ProfessorGavinPainterisdevelopingnewtreatmentsforcancerthatharnessthebody’sownimmunesystemtofightthedisease.ThiscancerimmunotherapyworkispartofanongoingcollaborationwithimmunologistsattheMalaghanInstituteofMedicalResearch.Unlikechemotherapeuticagentsthattargetmalignanttissuedirectly,cancervaccinestargettheimmunesystem.Theyarewelltoleratedbythebodyandhavefewersideeffectsthantraditionaltreatments.“Thevaccineskick-starttheimmunesystem,whichsendsitsowncellstokillthemalignanttissue.“Toincreasevaccinespecificityandpotencyweareusingleadingedgeconjugationandlinkerstrategiestomakenewclassesofsyntheticvaccinesthattargetthevaccinecomponentstospecialisedimmunecells.”Gavincollaborateswithsyntheticchemists,pharmacologists,immunologistsandcliniciansfromOtago,VictoriaandAucklanduniversitiesandCapital&CoastDistrictHealthBoard.HelooksforwardtoseeingtheNewZealand-basedresearchcommercialisedinthiscountry.

http://www.zcmsonline.com/index.php/zkzj/101093.html

  • 联系方式:
  • 手机号码:
  • 联系邮箱:
  • 助理电话:

详细介绍

Gavin Painter, Professor of Victoria University of Wellington, Lower Hutt, New Zealand. Professor Gavin Painter is developing new treatments for cancer that harness the body’s own immune system to fight the disease. This cancer immunotherapy work is part of an ongoing collaboration with immunologists at the Malaghan Institute of Medical Research.Unlike chemotherapeutic agents that target malignant tissue directly, cancer vaccines target the immune system. They are well tolerated by the body and have fewer side effects than traditional treatments.“The vaccines kick-start the immune system, which sends its own cells to kill the malignant tissue. “To increase vaccine specificity and potency we are using leading edge conjugation and linker strategies to make new classes of synthetic vaccines that target the vaccine components to specialised immune cells.”Gavin collaborates with synthetic chemists, pharmacologists, immunologists and clinicians from Otago, Victoria and Auckland universities and Capital & Coast District Health Board. He looks forward to seeing the New Zealand-based research commercialised in this country.